BioSpace News Archive

Scholar Rock today provided recent corporate updates and highlighted upcoming priorities for its pipeline programs in 2022.

Apyx Medical Corporation today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2021.

Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA ® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout.

Oncology Pharma Inc. provided an update on its progress to kick off the new year.

Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, announced the official opening of the second downstream processing suite within the company’s existing Myford North facility.

23andMe Holding Co., a leading consumer genetics and research company, received FDA clearance for a genetic health risk report on a hereditary prostate cancer marker.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, announced that Dr. Dominic F. Labriola has joined Madrigal as Senior Vice President and Chief Data and Analytics Officer.

BioCardia®, Inc., a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and respiratory diseases, announced it will be delivering virtual presentations during two investor meetings:

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, provided program updates and announced upcoming key milestones that are expected to substantially broaden and advance the company’s clinical pipeline.

Cara Therapeutics, Inc. (Nasdaq: CARA), today announced that its licensing partner Maruishi Pharmaceutical Co., Ltd., and its sublicensee Kissei Pharmaceutical Co., Ltd., confirmed the primary endpoint was achieved in a Japanese Phase 3 clinical study (double-blind, placebo-controlled period) of difelikefalin injection for the treatment of pruritus in hemodialysis patients.